WuXi Biologics Commences Construction on CRDMO Facility in Singapore

WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion. It will add 120,000L of manufacturing capacity to WuXi Biologics’ global network, and is expected to employ 1,500 staff.

The site will be equipped with WuXi Biologics’ proprietary technical platforms, along with industry-leading technologies such as single-use technology to provide clients with time-and cost-efficient services. In line with WuXi Biologics’ Environmental, Social and Governance strategy, the site will implement sustainable concepts in the design and construction of the center, deploy digital tools and build energy-saving facilities.

Mr. Png Cheong Boon, Chairman of EDB said, “WuXi Biologics Singapore CRDMO center will strengthen Singapore’s biopharmaceutical sector, which comprises global healthcare companies operating best-in-class manufacturing and R&D facilities, complemented by a strong local R&D and start-up ecosystem. This investment will create significant employment opportunities for Singaporeans, and spur collaborations between WuXi Biologics, our R&D institutions and startups to develop innovative therapeutics and novel modalities. Singapore continues to welcome global healthcare players seeking to innovate, manufacture and commercialize end-to-end solutions for clients worldwide.”

Mr.Alvin Tan, JTC’s Assistant Chief Executive Officer for Industry Cluster Group said, “As the master planner and developer for Singapore’s industrial estates, JTC is committed to cultivating a collaborative ecosystem of like-minded partners within our estates to strengthen Singapore’s position as a biomedical sciences hub. We are delighted that WuXi Biologics will be establishing its CRDMO center in Tuas Biomedical Park to be part of our ecosystem.”

Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are excited to enhance our capacity and geographic footprint by building a new CRDMO center in Singapore to serve the growing demands from the global and emerging Asia-Pacific markets. Our Singapore CRDMO center will provide high-quality and more cost-efficient end-to-end CRDMO services near where our clients operate through our Global Dual Sourcing strategy. As we continue to strengthen our global network, elevate our capacity and capabilities, and advance our technology platforms, we are better positioned to accelerate and transform the discovery, development and manufacturing of innovative biologics to enable global clients to bring their breakthrough therapeutics to patients worldwide.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter